Kato T, Kimura T, Miyakawa R, Tanaka S, Kamio T, Yamamoto K, Hamano K, Aiba M, Kawakami M
Department of Surgery II, Tokyo Women's Medical College, Shinjuku-ku, Japan.
Surg Today. 1996;26(2):105-14. doi: 10.1007/BF00311773.
This study was undertaken to assess blood vessel invasion (BVI) and other histologic features to determine the best method of histologic prognosis in node-negative breast cancer patients. The prognostic significance of the clinico-pathological findings was evaluated in 70 patients with node-negative breast cancer among 135 patients operated on between 1971 and 1981. The prognostic factors investigated included BVI, peritumor lymphatic invasion, clinical tumor size, nuclear grade, histological grade, mitotic grade, and tumor necrosis. BVI was detected by factor VIII-related antigen and elastica van Gieson staining. BVI-negative patients had a 20-year cumulative survival of 93.7%, versus 74.7% for BVI-positive patients (P = 0.0294). The clinical tumor size also correlated well with prognosis (P < 0.001). However, the other histologic features did not correlate with a poor prognosis. Moreover, we retrospectively examined the effect of postoperative chemotherapy for patients with BVI and T3, and the prognosis of those given chemotherapy seemed to be better than that of those who were not. Tumors measuring more than 51 mm and BVI may thus represent adverse prognostic factors in node-negative breast cancer patients.
本研究旨在评估血管侵犯(BVI)及其他组织学特征,以确定腋窝淋巴结阴性乳腺癌患者的最佳组织学预后评估方法。在1971年至1981年间接受手术的135例患者中,对70例腋窝淋巴结阴性乳腺癌患者的临床病理结果的预后意义进行了评估。研究的预后因素包括BVI、肿瘤周围淋巴管侵犯、临床肿瘤大小、核分级、组织学分级、有丝分裂分级和肿瘤坏死。通过因子VIII相关抗原和弹性纤维染色检测BVI。BVI阴性患者的20年累积生存率为93.7%,而BVI阳性患者为74.7%(P = 0.0294)。临床肿瘤大小也与预后密切相关(P < 0.001)。然而,其他组织学特征与不良预后无关。此外,我们回顾性研究了BVI和T3患者术后化疗的效果,接受化疗患者的预后似乎优于未接受化疗者。因此,肿瘤大小超过51 mm和BVI可能是腋窝淋巴结阴性乳腺癌患者的不良预后因素。